Actinium Pharmaceuticals, Inc. $ATNM Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its holdings in shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) by 35.4% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 97,604 shares of the company’s stock after purchasing an additional 25,511 shares during the period. Charles Schwab Investment Management Inc. owned about 0.31% of Actinium Pharmaceuticals worth $157,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ATNM. Deutsche Bank AG lifted its position in Actinium Pharmaceuticals by 413.6% during the fourth quarter. Deutsche Bank AG now owns 123,134 shares of the company’s stock valued at $155,000 after purchasing an additional 99,158 shares during the period. Nuveen Asset Management LLC lifted its position in Actinium Pharmaceuticals by 49.5% during the fourth quarter. Nuveen Asset Management LLC now owns 148,560 shares of the company’s stock valued at $187,000 after purchasing an additional 49,214 shares during the period. Squarepoint Ops LLC lifted its position in Actinium Pharmaceuticals by 25.4% during the fourth quarter. Squarepoint Ops LLC now owns 183,262 shares of the company’s stock valued at $231,000 after purchasing an additional 37,159 shares during the period. Bank of America Corp DE raised its position in shares of Actinium Pharmaceuticals by 76.6% in the fourth quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock worth $99,000 after acquiring an additional 34,176 shares during the period. Finally, AM Investment Strategies LLC raised its position in shares of Actinium Pharmaceuticals by 114.1% in the first quarter. AM Investment Strategies LLC now owns 30,872 shares of the company’s stock worth $50,000 after acquiring an additional 16,450 shares during the period. 27.50% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ATNM has been the subject of a number of analyst reports. HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of Actinium Pharmaceuticals in a research report on Tuesday, June 24th. Wall Street Zen downgraded shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, May 12th. Two equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $4.50.

Actinium Pharmaceuticals Trading Down 1.2%

Shares of NYSE ATNM opened at $1.69 on Friday. Actinium Pharmaceuticals, Inc. has a 12-month low of $1.03 and a 12-month high of $2.41. The stock has a market cap of $52.72 million, a PE ratio of -1.22 and a beta of -0.30. The company has a 50-day moving average of $1.62 and a 200 day moving average of $1.50.

Actinium Pharmaceuticals Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).